Meet Our Team
PHLBI is a freestanding nonprofit research facility committed to advancing medical research that may lead to new treatments, early detection, and prevention programs for chronic disorders, including cancer. Our staff is dedicated to discovering therapeutic breakthroughs involving cutting-edge pharmacologic, surgical, and other therapies that are as minimally invasive as possible for the patient.
Our Team consists of Clare Cameron, Executive Director of The Pacific Meso Center (PMC) at Pacific Heart, Lung & Blood Institute (PHLBI); Raymond Wong, Ph.D. Research Scientist; Irina Ianculescu, Ph.D., Research Scientist; and Dongmei Hou, M.D., Ph.D. Research Scientist. Our small staff functions in multiple capacities to maximize the use of our human and fiscal resources for administration, research, and health consumer education. All of our work is ultimately designed to inform patients—and give them the best treatment options–about malignant pleural mesothelioma and other degenerative diseases of the lungs, blood, and heart.
Clare Cameron offers more than a decade of fundraising and administrative experience as Senior Campaign Director of The Leukemia & Lymphoma Society where she helped procure millions of dollars for research on childhood leukemia. As the Administrator of PHLBI, she provides executive oversight of operations, finance, conferences, fundraising, media relations, and liaison relations with collaborative organizations such as UCLA School of Medicine. Ms. Cameron also coordinates the activity of volunteers, including students, who donate their time and talent to PHLBI,
Drs. Raymond Wong, Irina Ianculescu, Dongmei Hou, and Marko Kostic are experienced researchers who have worked on cancer-related projects in academia or industry, or both. They are presently investigating the use of adjuvant biologic therapies and cryotherapy for tumor reduction. Cryotherapy has recently garnered praise for its possible benefits in treating various types of cancer. Cryotherapy creates conditions in which a destroyed tumor functions as a “vaccine” for other tumor-ridden areas of the body.
Drs. Wong, Ianculescu, Hou, and Kostic have a unique combined expertise in immunotherapy, chemotherapy, therapeutic cancer vaccination, molecular biology, hyperthermia therapy, and bioengineering. They also prepare study reports on the results of their studies for publications and conferences.
While PHLBI currently focuses on pre-clinical science, or test tube studies, our research staff works closely with our offsite collaborators involved in clinical assessments of new treatments for cancer and other chronic diseases. In addition to performing scientific duties, our in-house scientists draw on their leadership experience at previous institutions to formulate and implement PHLBI’s intramural and extramural research strategies.